VANCOUVER, BC, Oct. 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the Company's DPX™ formulations. 

Dr. Rajagopalan has a PhD in Pharmaceutical Chemistry/Physical Chemistry, with over 20 years of experience in nanoparticles formulation development for biomolecules (peptides, proteins, nucleic acids, VLPs, mAbs) delivery to treat cancer, infectious diseases and autoimmune disorders. Most recently, Dr. Rajagopalan was Senior Director of Formulation Development at IMV, Inc., where he developed DPX-based vaccines to treat breast, ovarian, bladder and hard to reach cancers; and DPX-based RSV, Anthrax, ZIKA, Ebola, Tuberculosis and SARS infectious disease vaccines, as well as VLP-encapsulated DPX vaccines to treat Malaria and RSV infections. He also developed the DPX formulations for SurMAGE and KRAS/BRAS antigens to treat bladder and colorectal cancers, and formulation technology to deliver multiple peptides (up to 25 neoantigens) in a single DPX formulation for personalized cancer treatment, and an emulsion technology to co-deliver both small molecules chemotherapeutics and antibodies together for cancer treatments. In addition, Dr. Rajagopalan established that DPX technology can be used as a thermostable platform for vaccines with the inclusion of right additives (sugars and biodegradable polymers). Dr. Rajagopalan holds multiple patents to treat cancer and infectious diseases using DPX technology for the delivery of peptides, proteins, nucleic acids and small molecules. Dr. Rajagopalan currently works for Toralgen Inc., as VP Formulation/Manufacturing and Scientific Development, overseeing the formulation development and CMC activities for the oral delivery of GLP-1 peptides and mAbs.